Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 1, 2013, Pages

  Hizo Abes, Patricia ^a   Clark, William F ^a   Sontrop, Jessica M ^a   Young, Ann ^a   Huang, Anjie ^b   Thiessen Philbrook, Heather ^a   Austin, Peter C ^b   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ESCHERICHIA COLI; FEMALE; GASTROENTERITIS; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; SOCIAL CLASS;

EID: 84872146873     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.112161     Document Type: Article

References (56)

1. US Food and Drug Administration. Bad bug book - foodborne pathogenic microorganisms and natural toxins. 2nd edition. Silver Spring (MD): The Administration; 2012. Avaliable: www.fda.gov/Food/FoodSafety/FoodborneIllness/ FoodborneIllnessFoodbornePathogensNaturalToxins/BadBugBook/default.htm.
2. E. coli outbreak investigations. Atlanta (GA): Centers for Disease Control and Prevention; 2011. Available: www.cdc.gov/ecoli/outbreaks.html (accessed 2011 July 5).
3. Public Health Agency of Canada. Public health notice: E. coli O157 illness related to beef. Ottawa (ON): The Agency; 2012. Available: www.phac-aspc.gc.ca/fs-sa/phn-asp/ecoli-1012-eng.php (accessed 2012 Nov. 1).
4. Outbreak of Shiga toxin-producing E. coli in Germany. Stockholm (Sweden); 2011. Available: http://ecdc.europa.eu/en/activities/sciadvice/Lists/ ECDC%20Reviews/ECDC-DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6- bf0f23083f30&ID=1120&RootFolder= %2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20 Reviews (accessed 2011 July 5).
5. The World Health Organization. EHEC outbreak: update 13. Geneva (Switzerland): The Organization; 2011. Available: www.euro.who.int/en/what-we- do/health-topics/emergencies/international-health-regulations/news/news/2011/06/ ehec-outbreak-update-13 (accessed 2011 July 5).
6. Hughes AK, Stricklett PK, Kohan DE. Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells. Kidney Int 1998;54:426-37.
7. Hughes AK, Ergonul Z, Stricklett PK, et al. Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression [published erratum in J Am Soc Nephrol 2003 May;14:(5)]. J Am Soc Nephrol 2002;13:2239-45.
8. Van Setten PA, van Hinsbergh VW, Van den Heuvel LP, et al. Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms. J Am Soc Nephrol 1997;8:1877-88.
9. Matsushita K, van der Velde M, Astor BC; Chronic Kidney Disease Prognosis Consortium, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
10. Ohmi K, Kiyokawa N, Takeda T, et al. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem Biophys Res Commun 1998;251:137-41.
11. Obrig TG, Louise CB, Lingwood CA, et al. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993;268:15484-8.
12. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831-46.
13. van Setten PA, van Hinsbergh VW, van der Velden TJ, et al. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997;51:1245-56.
14. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, et al. Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect Immun 2005;73:8306-16.
15. Louise CB, Obrig TG. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991;59:4173-9.
16. Obrig TG, Del Vecchio PJ, Brown JE, et al. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun 1988;56:2373-8.
17. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 2002;105:15-21.
18. Lowe GD. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 2001;6:1-8.
19. Mehta JL, Saldeen T, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217-25.
20. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
21. Salvadori MI, Sontrop JM, Garg AX, et al. Factors that led to the Walkerton tragedy. Kidney Int Suppl 2009;(112):S33-4.
22. The investigative report of the Walkerton outbreak of waterborne gastroenteritis. Owen Sound (ON): Bruce-Grey Owen Sound Health Unit; 2000.
23. Clark WF, Sontrop JM, Macnab JJ, et al. Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 2010;341:c6020.
24. Rangel JM, Sparling PH, Crowe C, et al. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg Infect Dis 2005;11:603-9.
25. Su C, Brandt LJ. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995;123:698-714.
26. Garg AX, Macnab J, Clark W, et al. Long-term health sequelae following E. coli and Campylobacter contamination of municipal water. Population sampling and assessing non-participation biases. Can J Public Health 2005;96:125-30.
27. Garg AX, Moist L, Matsell D, et al. Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. CMAJ 2005;173:261-8.
28. Garg AX, Marshall J, Salvadori M, et al. A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. J Clin Epidemiol 2006;59:421-8.
29. 2006 Community profiles . Cat. no. [92-591-XWE]. Ottawa (ON): Statistics Canada; 2006.
30. Institute for Clinicial Evaluative Sciences. ICES data holdings. Toronto (ON): The Institute for; 2011. Available: www.ices.on.ca/webpage.cfm?site-id= 1&org-id=26&morg-id=0&gsec-id=5314&item-id=5322 (accessed 2010 July 6).
31. Siddiqui NF, Coca SG, Devereaux PJ, et al. Secular trends in acute dialysis after elective major surgery - 1995 to 2009. CMAJ 2012;184:1237-45.
32. Shih AW, Weir MA, Clemens KK, et al. Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney Int 2012;82:903-8.
33. Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 2012;156:560-9.
34. Garg AX, Meirambayeva A, Huang A, et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ 2012;344:e1203.
35. Molnar AO, Coca SG, Devereaux PJ, e al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22:939-46.
36. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J 2002;144:290-6.
37. Canadian Institute for Health Information. Discharge abstract database data quality re-abstraction study: Combined findings for 1999/2000 and 2000/2001. 2002. Ottawa (ON): The Institute; 2002.
38. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
39. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992;82:243-8.
40. Henderson T, Shepheard J, Sundararajan V. Quality of diagnosis and procedure coding in ICD-10 administrative data. Med Care 2006;44:1011-9.
41. Jha P, Deboer D, Sykora K, et al. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. J Am Coll Cardiol 1996;27:1335-42.
42. Juurlink DN, Prevra C, Croxford R. Canadian Institute for Health Information Discharge Abstract Database: a validation study. Toronto (ON): Institute for Clinical Evaluative Sciences; 2006.
43. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002;40:675-85.
44. Richards J, Brown A, Homan C. The data quality study of the Canadian discharge abstract database. In: Achieving data quality in a statistical agency. Ottawa (ON): Statistics Canada; 2002.
45. Greenland S, Rothman K. Introduction to stratified analysis. In: Rothman K, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998. p. 253-79.
46. Kennedy WJ, Bancroft TA. Model building for prediction in regression based upon repeated significance tests. Ann Math Stat 1971;42:1273-84.
47. Lee KI, Koval JJ. Determination of the best significance level in forward stepwise logistic regression. Comm Statist Simulation Comput 1997;26:559-75.
48. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
49. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989;129:125-37.
50. Wilkins R. PCCF + Version 4J user's guide: automated geographic coding based on the Statistics Canada postal code conversion files. Ottawa (ON): Statistics Canada; 2007. Cat. No. 82F0086-XDB. Available: http://prod.library. utoronto.ca/datalib/codebooks/cstdli/pccf-health/pccf4j/msword.pccf4j.pdf (accessed 2012 June 6).
51. Austin PC, Walraven C. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins Aggregated Diagnosis Groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care 2011;49:940-7.
52. Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption. Survival analysis. 2nd ed. New York (NY): Springer; 2005. p. 131-71.
53. Clark WF, Macnab JJ, Sontrop JM; WEL Investigators of the Walkerton Health Study. London (ON): The Walkerton Health Study, 2002-2008: final report; 2008.
54. Table 102-0552: Deaths and mortality rate, by selected grouped causes and sex, Canada, provinces and territories, annual. Ottawa (ON): Statistics Canada; 2007. Available: www5.statcan.gc.ca/cansim/a01?lang=eng (accessed 2011 July 11).
55. Shariff SZ, Cuerden MS, Jain AK, et al. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008;19:841-3.
56. Lévesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087.